Suscribirse

Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase ? syndrome–like immunodeficiency - 18/04/17

Doi : 10.1016/j.jaci.2016.03.055 
Yuki Tsujita, MD a, , Kanako Mitsui-Sekinaka, MD a, , Kohsuke Imai, MD, PhD a, b, , Tzu-Wen Yeh, MSc c, Noriko Mitsuiki, MD, PhD c, Takaki Asano, MD d, Hidenori Ohnishi, MD, PhD e, Zenichiro Kato, MD, PhD e, f, Yujin Sekinaka, MD a, Kiyotaka Zaha, MD a, Tamaki Kato, MD, PhD a, Tsubasa Okano, MD c, Takehiro Takashima, MD c, Kaoru Kobayashi, MD, PhD g, Mitsuaki Kimura, MD, PhD h, Tomoaki Kunitsu, MD i, Yoshihiro Maruo, MD, PhD i, Hirokazu Kanegane, MD, PhD c, Masatoshi Takagi, MD, PhD c, Kenichi Yoshida, MD, PhD j, Yusuke Okuno, MD, PhD k, Hideki Muramatsu, MD, PhD k, Yuichi Shiraishi, PhD l, Kenichi Chiba, BA l, Hiroko Tanaka, BSc m, Satoru Miyano, PhD l, m, Seiji Kojima, MD, PhD k, Seishi Ogawa, MD, PhD j, Osamu Ohara, PhD n, Satoshi Okada, MD, PhD d, Masao Kobayashi, MD, PhD d, Tomohiro Morio, MD, PhD c, Shigeaki Nonoyama, MD, PhD a
a Department of Pediatrics, National Defense Medical College, Saitama, Japan 
b Department of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan 
c Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan 
d Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan 
e Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu, Japan 
f Structural Medicine, United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan 
g Department of Surgery, Kuma Hospital, Kobe, Japan 
h Department of Allergy and Clinical Immunology, Shizuoka Children's Hospital, Shizuoka, Japan 
i Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan 
j Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan 
k Department of Pediatrics, Nagoya University Gradual School of Medicine, Nagoya, Japan 
l Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science University of Tokyo, Tokyo, Japan 
m Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science University of Tokyo, Tokyo, Japan 
n Department of Technology Development, Kazusa DNA Research Institute, Chiba, Japan 

Corresponding author: Kohsuke Imai, MD, PhD, Department of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.Department of Community PediatricsPerinatal and Maternal MedicineTokyo Medical and Dental University, 1-5-45Yushima, Bunkyo-kuTokyo113-8519Japan

Abstract

Background

Activated phosphatidylinositol 3-kinase δ syndrome (APDS) is a recently discovered primary immunodeficiency disease (PID). Excess phosphatidylinositol 3-kinase (PI3K) activity linked to mutations in 2 PI3K genes, PIK3CD and PIK3R1, causes APDS through hyperphosphorylation of AKT, mammalian target of rapamycin (mTOR), and S6.

Objective

This study aimed to identify novel genes responsible for APDS.

Methods

Whole-exome sequencing was performed in Japanese patients with PIDs. Immunophenotype was assessed through flow cytometry. Hyperphosphorylation of AKT, mTOR, and S6 in lymphocytes was examined through immunoblotting, flow cytometry, and multiplex assays.

Results

We identified heterozygous mutations of phosphatase and tensin homolog (PTEN) in patients with PIDs. Immunoblotting and quantitative PCR analyses indicated that PTEN expression was decreased in these patients. Patients with PTEN mutations and those with PIK3CD mutations, including a novel E525A mutation, were further analyzed. The clinical symptoms and immunologic defects of patients with PTEN mutations, including lymphocytic AKT, mTOR, and S6 hyperphosphorylation, resemble those of patients with APDS. Because PTEN is known to suppress the PI3K pathway, it is likely that defective PTEN results in activation of the PI3K pathway.

Conclusion

PTEN loss-of-function mutations can cause APDS-like immunodeficiency because of aberrant PI3K pathway activation in lymphocytes.

El texto completo de este artículo está disponible en PDF.

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Key words : Activated phosphatidylinositol 3-kinase δ syndrome, catalytic subunit p110δ of phosphatidylinositol 3-kinase, phosphatase and tensin homolog, primary immunodeficiency disease

Abbreviations used : APDS, BRRS, CS, CVID, FITC, GAPDH, GOF, IVIG, KREC, LOF, mTOR, NK, pAKT, PCP, PET, PID, PI3K, PIP2, PIP3, pmTOR, pS6, PTEN, qPCR, ST, TFH, TrB, TREC


Esquema


 Supported in part by the Ministry of Defense, Japan; the Research on Measures for Intractable Diseases Project (H26-037, H23-012): matching fund subsidy from the Ministry of Health, Labour and Welfare, Japan; the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (26293250, 15K09640); the Practical Research for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED; the Japan Foundation for Pediatric Research; the Jeffrey Modell Foundation; the Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics; and Drs M. and W. Hirose, H. Matsuda, and H. Seto.
 Disclosure of potential conflict of interest: K. Imai has received research support from the Japan Foundation for Pediatric Research and CSL Behring KK and has received consultancy and lecture fees from CSL Behring. The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 138 - N° 6

P. 1672 - décembre 2016 Regresar al número
Artículo precedente Artículo precedente
  • Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy
  • Marcel Frick, Jörg Fischer, Arthur Helbling, Franziska Ruëff, Dorothea Wieczorek, Markus Ollert, Wolfgang Pfützner, Sabine Müller, Johannes Huss-Marp, Britta Dorn, Tilo Biedermann, Jonas Lidholm, Gerta Ruecker, Frank Bantleon, Michaela Miehe, Edzard Spillner, Thilo Jakob
| Artículo siguiente Artículo siguiente
  • X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene
  • Chantal Lagresle-Peyrou, Sonia Luce, Farid Ouchani, Tayebeh Shabi Soheili, Hanem Sadek, Myriam Chouteau, Amandine Durand, Isabelle Pic, Jacek Majewski, Chantal Brouzes, Nathalie Lambert, Armelle Bohineust, Els Verhoeyen, François-Loïc Cosset, Aude Magerus-Chatinet, Frédéric Rieux-Laucat, Virginie Gandemer, Delphine Monnier, Catherine Heijmans, Marielle van Gijn, Virgil A. Dalm, Nizar Mahlaoui, Jean-Louis Stephan, Capucine Picard, Anne Durandy, Sven Kracker, Claire Hivroz, Nada Jabado, Geneviève de Saint Basile, Alain Fischer, Marina Cavazzana, Isabelle André-Schmutz

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.